Vir, Gilead team up on solid tumor cancer therapies in up to $1.9 billion deal
GILD•Vir Biotechnology signed a collaboration agreement with Gilead Sciences worth up to $1.88 billion to develop solid tumor cancer treatments. Vir will receive $90 million upfront and may earn up to $45 million in near-term milestones, up to $1.74 billion in future payments and tiered royalties.
1. Deal terms
Vir said it signed a collaboration agreement with Gilead Sciences to discover and develop new cancer treatments for solid tumors. The deal provides Vir with $90 million upfront, up to $45 million in near-term preclinical milestones and up to $1.74 billion in future development, regulatory and commercial payments, as well as tiered royalties ranging from high single digits to low double digits.
2. Research and development
The partnership aims to engineer three dual-masked T-cell engager candidates. Vir will use its PRO-XTEN masking technology and dAIsY AI platform for early research and drug design, while Gilead will hold exclusive rights to advance the candidates through clinical testing, manufacturing and commercialization.
